FDA Delays Approval For MannKind's Inhaled Insulin Afrezza, Stoking Confusion
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency will miss the Jan. 16 action date for the NDA due to a manufacturing inspection; but how the potential length of the delay remains to be seen.